Caremark exits home infusion with $310 mil. sale of division to Coram.
Executive Summary
CAREMARK EXITS HOME INFUSION WITH $310 MIL. SALE TO CORAM of the assets of Caremark's home infusion business under a definitive agreement announced Jan. 30. Caremark will receive "approximately $310 mil. in cash and securities, subject to post-closing adjustment, in exchange for the assets of its home infusion business," Caremark said. The figure breaks down to $210 mil. in cash, $75 mil. in 7% convertible subordinated notes and $25 mil in 12% non-convertible subordinated notes, Caremark said.